Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oncologic outcome and safety profile of first-line enfortumab vedotin plus pembrolizumab vs. conventional chemotherapy in advanced urothelial cancer.

Exploration of targeted anti-tumor therapy·2026
Same author

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Sarcopenia Weakens the Benefit of Bacillus Calmette-Guérin in Non-Muscle-Invasive Bladder Cancer: A Computed Tomography-Based Cohort Study.

International journal of urology : official journal of the Japanese Urological Association·2026
Same author

Detection of bladder cancer in patients with microscopic hematuria using Oncuria-Detect: results of a prospective, multicenter international study.

Journal of translational medicine·2026
Same author

Changes of urinary immunity and microbiome after intravesical BCG therapy and their association with outcomes in NMIBC.

Exploration of targeted anti-tumor therapy·2026
Same author

ASO Visual Abstract: Fluorescent Ureterorenoscopy-Assisted Thulium:YAG and Holmium:YAG Dual Laser Ablation for Upper Urinary Tract Urothelial Carcinoma: Results of the FLUAM Trial.

Annals of surgical oncology·2026

Related Experiment Video

Updated: Sep 13, 2025

Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method
14:48

Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method

Published on: July 6, 2012

43.8K

Expanded Performance Comparison of the Oncuria 10-Plex Bladder Cancer Urine Assay Using Three Different Luminex xMAP

Sunao Tanaka1, Takuto Shimizu1, Ian Pagano2

  • 1Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Diagnostics (Basel, Switzerland)
|July 29, 2025
PubMed
Summary

The Oncuria bladder cancer (BC) assay accurately measures 10 urinary protein biomarkers across multiple Luminex analyzers. This validated assay supports BC diagnosis and treatment monitoring, showing consistent performance for broad clinical adoption.

Keywords:
bladder cancerdynamic rangefluorescencemagnetic beadmultiplex immunoassayperformancexMAP technology

More Related Videos

Author Spotlight: Engineering Molecular Tools for Disease Detection and Imaging
04:33

Author Spotlight: Engineering Molecular Tools for Disease Detection and Imaging

Published on: December 8, 2023

993
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.3K

Related Experiment Videos

Last Updated: Sep 13, 2025

Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method
14:48

Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method

Published on: July 6, 2012

43.8K
Author Spotlight: Engineering Molecular Tools for Disease Detection and Imaging
04:33

Author Spotlight: Engineering Molecular Tools for Disease Detection and Imaging

Published on: December 8, 2023

993
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.3K

Area of Science:

  • Urology
  • Oncology
  • Biomarker Discovery

Background:

  • The Oncuria assay is a validated, noninvasive method for bladder cancer (BC) risk assessment and treatment monitoring.
  • It simultaneously profiles 10 protein biomarkers in urine using multiplex technology.

Purpose of the Study:

  • To compare the performance of the Oncuria BC assay across three different Luminex instrumentation platforms.
  • To validate the assay's consistency in a larger patient cohort.

Main Methods:

  • The Oncuria assay was performed on urine samples from 181 subjects (51 with BC).
  • Performance was evaluated across three Luminex analyzers: FlexMap 3D, Luminex 200, and MagPix.
  • Assay concordance, coefficient of variation (%CV), and correlation (R^2) were analyzed for 10 protein biomarkers.

Main Results:

  • Excellent concordance was observed for all 10 analytes across the three analyzers.
  • The %CV for protein concentrations was ≤2.3% for 9 out of 10 analytes.
  • High correlation (R^2 ≥ 0.995 for 27/30 comparisons) was found between instruments, with carbonic anhydrase IX (CA9) showing the greatest variability.

Conclusions:

  • The Oncuria BC assay provides comprehensive urinary protein signatures for BC diagnosis and management.
  • Equivalent assay performance across popular analyzers supports its adoption in clinical and research laboratories.
  • The assay aids in predicting treatment response and tracking disease progression or recurrence.